<DOC>
	<DOCNO>NCT02787824</DOCNO>
	<brief_summary>The purpose study compare efficacy two regimens intravenous iron sucrose [ continuous ( every hemodialysis session ) versus intermittent ( every 1-4 week ) ] response rHuEPO maintenance phase administration hemodialysis patient .</brief_summary>
	<brief_title>Periodic Versus Continuous IV Iron Supplementation HD Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Constant rHuEPO iron dose least 2 month start study Hemoglobin â‰¥ 8,5g/dl &lt; 12,5 g/dl Ferritin &lt; 1000 mg/dl TSAT &lt; 50 % CRP &lt; 5 mg/dl Malignant tumor disease Oral iron supplementation Active bleeding issue Surgical intervention within last 8 week study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>iron deficiency</keyword>
	<keyword>hemodialysis</keyword>
</DOC>